Renaissance Technologies LLC purchased a new position in Caribou Biosciences, Inc. (NASDAQ:CRBU – Free Report) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 1,482,900 shares of the company’s stock, valued at approximately $2,432,000.
A number of other large investors also recently modified their holdings of CRBU. Avidity Partners Management LP raised its position in shares of Caribou Biosciences by 5.1% during the 4th quarter. Avidity Partners Management LP now owns 6,360,212 shares of the company’s stock worth $36,444,000 after buying an additional 310,000 shares in the last quarter. Vanguard Group Inc. raised its holdings in Caribou Biosciences by 3.8% during the first quarter. Vanguard Group Inc. now owns 4,110,795 shares of the company’s stock worth $21,129,000 after purchasing an additional 148,751 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Caribou Biosciences by 25.7% during the second quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock worth $4,302,000 after purchasing an additional 536,162 shares in the last quarter. Wellington Management Group LLP boosted its stake in Caribou Biosciences by 57.7% during the 4th quarter. Wellington Management Group LLP now owns 314,080 shares of the company’s stock valued at $1,800,000 after purchasing an additional 114,975 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Caribou Biosciences by 14.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 308,273 shares of the company’s stock valued at $506,000 after purchasing an additional 38,098 shares during the period. 77.51% of the stock is owned by institutional investors and hedge funds.
Caribou Biosciences Stock Down 6.6 %
Caribou Biosciences stock opened at $1.83 on Wednesday. Caribou Biosciences, Inc. has a 12 month low of $1.50 and a 12 month high of $8.33. The stock has a market cap of $165.28 million, a P/E ratio of -1.26 and a beta of 2.29. The company’s fifty day simple moving average is $2.06 and its 200-day simple moving average is $2.78.
Analyst Ratings Changes
Several analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Caribou Biosciences in a report on Tuesday, September 3rd. Royal Bank of Canada restated an “outperform” rating and issued a $14.00 price target on shares of Caribou Biosciences in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.25.
Check Out Our Latest Report on CRBU
About Caribou Biosciences
Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.
Further Reading
- Five stocks we like better than Caribou Biosciences
- What is a SEC Filing?
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Dividend Capture Strategy: What You Need to Know
- 2 Energy Stocks Fueling the AI Datacenter Boom
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Want to see what other hedge funds are holding CRBU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Caribou Biosciences, Inc. (NASDAQ:CRBU – Free Report).
Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.